EUCTR2016-000509-35-BG进行中（未招募）1 期
An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients with Active Mild to Moderate Ulcerative Colitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females, 18 to 70 years of age inclusive
- •2. Have had a diagnosis of ulcerative colitis per European guideline criteria for a minimum of 3 months by:
- •a. medical history
- •b. physical examination
- •c. laboratory tests (anemia, increased levels of C-reactive protein(CRP), fecal samples for blood)
- •d. histopathological evidence from flexible sigmoidoscopy or colonoscopy
- •3. Have active mild to moderate ulcerative colitis, as defined by a full Mayo score at Screening. Full Mayo score of 4 to 9 (inclusive) will consist of:
- •a. Stool frequency (Mayo subscore =1);
- •b. Rectal bleeding (Mayo subscore =1);
- •c. Endoscopic evidence of active mucosal disease (i.e., Mucosal appearance, Mayo subscore =1), as assessed by flexible sigmoidoscopy unless colonoscopy is clinically indicated.
- •d. Physician’s Global Assessment (PGA) of at least mild disease (Mayo sub-score =1).
- •4. If female, not be of childbearing potential, as evidenced by being surgically sterile or postmenopausal for at least 12 months, or be using acceptable contraception methods such as hormonal contraception or two forms of barrier contraception. Acceptable contraception must be used consistently from 30 days before Screening Visit through study completion.
- •5. If male, not be of fathering potential, as evidenced by being surgically sterile for at least 12 months, or be using double barrier methods of contraception (e.g. use of condom AND an acceptable contraception method by the female partner such as hormonal contraception).
- •6. If female, have a negative serum pregnancy test at Screening Visit and a negative urine pregnancy test at Baseline before administration of study treatment.
- •7. Be willing and able to adhere to the study visit schedule and other protocol requirements.
- •8. Be willing and able to provide voluntary written informed consent.
- •9. Have adequate cardiac, renal and hepatic functions as determined by the investigator and demonstrated by screening clinical and laboratory evaluations and physical examination results; these findings must all be within normal limits or judged not clinically significant by the investigator.
- •10. High level of calprotectin (>100 mg/kg of stool)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have a history of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy
- •2. Currently receiving total parenteral nutrition (TPN)
- •3. Positive for active / latent mycobacterium tuberculosis (TB) infection at the Screening Visit
- •4. Positive laboratory tests for HIV, HBs-Ag and HCV at the Screening Visit
- •5. Pregnant or breast-feeding, or plan to become pregnant during the study
- •6. Have a history of infection requiring administration of any IV antibiotic, antiviral or antifungal medication within 30 days of Screening Visit throughout study completion or any oral antiinfective agent within 14 days of Screening Visit or at any time during the study
- •7. Severe ulcerative colitis evidenced by the following signs of toxicity: heart rate >90 beats/min at rest, temperature >38.0°C
- •8. Ulcerative proctitis, defined as disease limited to less than 15 cm from the anal verge
- •9. Use a vaccine or other immunostimulator within 4 weeks prior to Screening Visit or any time during the study
- •10. Use >4.8 g 5-ASA or equivalent within 2 weeks prior to the Screening Visit or at any time during the study.
- •a. Use of 5-ASA or equivalent=4.8 g is allowed if the dose during the 2 weeks prior to the Screening Visit was stable, subject is to remain on stable dose through End of Study Visit (Week 10, Visit 7)
- •11. Use of corticosteroid or 5-ASA enemas, foams, or suppositories within two weeks prior to the Screening Visit or at any time during the study.
- •12. Use of anti-inflammatory medications (cromones, xanthines, leukotriene antagonists) or natural remedies (Probiotics, omega-3 fatty acids) within 4 weeks prior to ScreeningVisit or any time during the study
- •13. Use of oral or parenteral antibiotics within two weeks prior to the Screening Visit or at any time during the study.
- •14. Use of chronic non-steroidal anti-inflammatory (NSAID) therapy
- •a. Occasional use of NSAIDs and acetaminophen for headache, arthiritis, myalgias, menstrual cramps etc., as well as daily use of low-low dose (81-162 mg) aspirin for cardiovascular prophylaxis is permitted
- •15. Use of immune suppressive agents including anti-TNF agents, Azathioprine, 6MP, Methotrexate 12 weeks prior to Screening Visit or at any time during the study.
- •16. Use of steroids 12 weeks prior to Screening Visit or at any time during the study.
- •17. Have a diagnosis of:
- •a. Crohn’s disease;
- •b. Indeterminate colitis (inability to distinguish between ulcerative colitis and Crohn’s
- •c. Microscopic colitis (collagenous or lymphocytic colitis);
- •d. Ischemic or infectious colitis;
- •e. Clostridium difficile colitis at Screening Visitor within 90 days of the Screening Visit;
- •f. Parasitic disease within 90 days of the Screening Visit
- •18. Have a congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation)
- •19. Have clinically significant abnormal laboratory test results, unless regarded by the investigator as related to ulcerative colitis:
- •a. Hemoglobin level <10.5g/dL
- •b. White blood cell count < 3 x 103/µL
- •c. Lymphocyte count < 0.5 x 103/µL
- •d. Platelet count < 100 x 103/µL or > 1200 x 103/µL
- •e. Alanine aminotranseferase (ALT) or apartate aminotransferase (AST) > 3 x the upper limit of normal (ULN)
- •f. Alkaline phosphatase >3 x ULN
- •g. Serum creatinine > 2 x ULN
- •20. Active abuse of alcohol or illicit drugs.
- •21. Have a known malignancy or history of malignancy that would reduce life expectancy.
- •22. Have any condition, which in the opinion of the investigator, would place
研究者
相似试验
已完成
不适用
A proof of concept study to evaluate the safety, efficacy and tolerability of Throat spray (LPOTC002-11) for relief of sore throat/throat paiCTRI/2012/08/002927aila Pharmaceuticals Pvt Ltd30
招募中
1 期
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones.Graves` diseaseMedDRA version: 26.0Level: PTClassification code 10018706Term: Graves' diseaseSystem Organ Class: 10014698 - Endocrine disordersEUCTR2022-002894-27-DEImmunovant Sciences GmbH45
进行中（未招募）
1 期
To find out whether LFG316 is able to reduce the destruction of red blood cells in patients with PNHParoxysmal nocturnal hemoglobinuriaMedDRA version: 21.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2014-005338-74-LTovartis Pharma Services AG9
已完成
2 期
Proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316 in patients with paroxysmal nocturnal hemoglobinuria (PNH)paroxysmal nocturnal hemoglobinuriaJPRN-jRCT2080223041ovartis Pharma K.K.10
进行中（未招募）
1 期
To find out whether LFG316 is able to reduce the destruction of red blood cells in patients with PNHParoxysmal nocturnal hemoglobinuriaMedDRA version: 21.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2014-005338-74-CZovartis Pharma Services AG9